Conexeu Sciences Inc. is an early-stage medical technology company. The Company is focused on developing regenerative biomaterials that address significant needs in wound care, dentistry, and aesthetics. The Company is focused on providing physicians with device-based solutions for healing, restoring soft tissue, and improving patient outcomes across multiple clinical settings. Its core device candidate, CXU, is a temperature-responsive ECM scaffold formulation intended to transition in-situ to a gel-like extra cellular matrix (ECM) within approximately minutes (Ten-Minute Tissue). The Company operates and manages its business in one operating segment, which is developing and commercializing novel cellular therapies for skin restoration in wound care and aesthetics.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
23/10/26	USD 3.100	-6.06%	167,705
22/10/26	USD 3.300	-0.90%	207,684
21/10/26	USD 3.330	+11.37%	417,807
20/10/26	USD 2.990	-9.12%	597,247
19/10/26	USD 3.290	+7.52%	390,336

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.100USD

Average target price

20.00USD

Spread / Average Target

+545.16%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Conexeu Sciences Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Conexeu Sciences Inc.

Company calendar

Market Closed - Nasdaq 07:00:00 24/10/26 am AEDT			5-day change	1st Jan Change
3.100 ^USD	-6.06%		+1.31%	-

16/10	Conexeu Sciences Closes $5 Million Private Placement	MT
15/10	Conexeu Sciences Inc. announced that it has received $5 million in funding	CI

Market Cap	87.44M 78.08M 72.14M 65.37M 122M 8.3B 124M 868M 344M 4.35B 328M 321M 13.71B	P/E 2026 *	-7.75x	P/E 2027 *	-5.85x
Enterprise Value	87.44M 78.08M 72.14M 65.37M 122M 8.3B 124M 868M 344M 4.35B 328M 321M 13.71B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	52.37%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	CNXU	Delayed
CBOE	CNXU	Real-time

16/10	Conexeu Sciences Closes $5 Million Private Placement	MT
15/10	Conexeu Sciences Inc. announced that it has received $5 million in funding	CI
07/10	Conexeu Sciences Shares Rise on Advancement of Tissue Restoration Platform	DJ
06/10	Conexeu Sciences Inc. Advances Ten Minute Tissue? Regulatory And Manufacturing Program Toward Planned FDA 510(k) Submission	CI
21/09	Conexeu Sciences Inc.(NasdaqCM:CNXU) added to S&P TMI Index	CI
15/09	Conexeu Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI
18/08	Conexeu Sciences Advances CXU Platform And Completes 12-Month P.R.O.O.F. Phase Of Preclinical Program	CI
14/07	Conexeu Sciences Details Completion Of 12-Month P.R.O.O.F. Preclinical Study For CXU Platform	CI
08/07	Conexeu Sciences Completes 12-Month Preclinical P.R.O.O.F Study for Cxu Platform and Announces Planned Move into Medical Aesthetics Market	CI
26/06	Conexeu Sciences Opens New Research and Development Facility At Admare M4 Innovation Centre in Vancouver	CI
25/06	Alert tagged to multiple companies from a research report withdrawn	RE
22/06	HC Wainwright Initiates Conexeu Sciences at Buy With $20 Price Target	MT
16/06	Conexeu Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI

Conexeu Sciences Inc. Stock

Stocks

CNXU

US20715F1003

Biotechnology & Medical Research

Valuation: Conexeu Sciences Inc.

Chart: Conexeu Sciences Inc.

Latest news: Conexeu Sciences Inc.

Analysts' recommendations: Conexeu Sciences Inc.

Press Releases: Conexeu Sciences Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Conexeu Sciences Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

06/10	Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission	AQ
01/09	Conexeu Sciences Sets September and October 2026 Conference Schedule	AQ
19/08	A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.	AQ
18/08	The Biggest Winners Don't Compete in a Category. They Rewrite It. One Company Is Betting It Can Too.	AQ
18/08	Conexeu Sciences : Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration	PU

1 day	-6.06%
1 week	+1.31%
Current month	-13.17%
1 month	-21.72%
3 months	-63.83%

1 week	2.95	3.6
1 month	2.95	4.36
Current year	2.95	18.79
1 year	2.95	18.79
3 years	2.95	18.79
5 years	2.95	18.79
10 years	2.95	18.79

Manager	Title	Age	Since
Miles Harrison CEO	Chief Executive Officer	61	23/10/2025
Claudia Chavez-Munoz CTO	Chief Tech/Sci/R&D Officer	46	16/10/2023
David Bogart PRN	Corporate Officer/Principal	56	15/06/2026

Director	Title	Age	Since
David Bogart BRD	Director/Board Member	56	13/11/2023
Jeffrey Nathan Sharpe CHM	Chairman	54	23/10/2025
Miles Harrison BRD	Director/Board Member	61	23/10/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
25/9/26	David Bogart	Exercice	Founder	1,500,000	5.6057%
14/9/26	Jeffrey Nathan Sharpe	Exercice	Chairman	1,000,000	3.7372%
26/5/26	Michael Wright	Exercice		800,000	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CONEXEU SCIENCES INC.	-6.06%	+1.31%	-	-	87.44M
WUXI APPTEC CO., LTD.	+2.41%	+0.29%	+39.41%	+72.14%	64.69B
ARGENX SE	-0.15%	+7.50%	+11.42%	+71.27%	54.78B
LONZA GROUP AG	+0.57%	+4.60%	+7.71%	+90.93%	53.49B
IQVIA HOLDINGS INC.	+0.37%	+4.67%	+26.68%	+49.64%	45.98B
BEONE MEDICINES AG	-1.21%	+2.32%	+21.50%	+118.33%	42.94B
REVOLUTION MEDICINES, INC.	-0.37%	+5.07%	+243.23%	+789.58%	40.08B
CELLTRION, INC.	+0.05%	+0.21%	+18.06%	+48.50%	33.52B
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-4.98%	+26.31%	-0.76%	23.97B
GENMAB A/S	-0.38%	+5.68%	+38.39%	+28.35%	23.67B
Average	-0.36%	+2.30%	+48.08%	+140.89%	38.32B
Weighted average by Cap.	+0.39%	+2.73%	+46.02%	+142.84%

	2026 *	2027 *
Net sales	-	-
Net income	-9.51M -8.49M -7.85M -7.11M -13.3M -903M -13.52M -94.43M -37.39M -473M -35.7M -34.94M -1.49B	-14.78M -13.2M -12.19M -11.05M -20.67M -1.4B -21.02M -147M -58.09M -735M -55.47M -54.29M -2.32B
Net Debt	-	-